141 related articles for article (PubMed ID: 25363327)
21. Occult hepatitis B virus infection in patients with chronic hepatitis C: An actor behind the scene or just a bystander?
Chu CJ; Lee SD
J Gastroenterol Hepatol; 2010 Feb; 25(2):221-3. PubMed ID: 20136983
[No Abstract] [Full Text] [Related]
22. NS5A sequences of hepatitis C virus genotype 1 and interferon resistance: where are we?
Germanidis G; Metallidis S; Lazaraki G; Pawlotsky JM; Nikolaidis P
J Infect Dis; 2008 Jul; 198(1):154-5. PubMed ID: 18544013
[No Abstract] [Full Text] [Related]
23. Focus.
Shouval D
J Hepatol; 2013 Dec; 59(6):1151-2. PubMed ID: 24021425
[No Abstract] [Full Text] [Related]
24. Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes.
Dahari H; Affonso de Araujo ES; Haagmans BL; Layden TJ; Cotler SJ; Barone AA; Neumann AU
J Hepatol; 2010 Sep; 53(3):460-7. PubMed ID: 20561702
[TBL] [Abstract][Full Text] [Related]
25. Treatment with recombinant alpha 2b-interferon of chronic HDV hepatitis in children.
Craxì A; Di Marco V; Volpes R; Marra S; Rizzetto M; Rosina F; Barbera C; Bortolotti F; Crivellaro C; Iannuzzi C
Prog Clin Biol Res; 1991; 364():399-404. PubMed ID: 2020715
[No Abstract] [Full Text] [Related]
26. Commentary: HBsAg levels as predictor of sustained response to peg interferon in HBeAg-negative chronic hepatitis B.
Hadziyannis SJ
Aliment Pharmacol Ther; 2012 Apr; 35(7):842-3; discussion 843-4. PubMed ID: 22404402
[No Abstract] [Full Text] [Related]
27. [Efficacy of new therapies].
Ongaro M; Spahr L; Giostra E; Negro F
Rev Med Suisse; 2020 Sep; 16(704):1538-1543. PubMed ID: 32880108
[TBL] [Abstract][Full Text] [Related]
28. Weight-based dosing regimen of peg-interferon α-2b for chronic hepatitis delta: a multicenter Romanian trial.
Gheorghe L; Iacob S; Simionov I; Vadan R; Constantinescu I; Caruntu F; Sporea I; Grigorescu M
J Gastrointestin Liver Dis; 2011 Dec; 20(4):377-82. PubMed ID: 22187703
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
[TBL] [Abstract][Full Text] [Related]
30. [New perspectives in the treatment of viral hepatitis C: pegylated interferon alpha].
Alric L; Cacoub P
Rev Med Interne; 2001 Oct; 22(10):922-5. PubMed ID: 11695314
[No Abstract] [Full Text] [Related]
31. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
Lukasiewicz E; Hellstrand K; Westin J; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Veldt BJ; Hansen BE; Verhey-Hart E; Lagging M
Hepatology; 2007 Jan; 45(1):258-9. PubMed ID: 17187414
[No Abstract] [Full Text] [Related]
32. Mechanism of action of ribavirin in anti-HCV regimens: new insights for an age-old question?
Testoni B; Levrero M; Durantel D
Gut; 2014 Jan; 63(1):3-4. PubMed ID: 23661602
[No Abstract] [Full Text] [Related]
33. Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs.
Huang J; Zhang K; Chen W; Liao J; Luo X; Chen R
Sci Rep; 2017 Oct; 7(1):13383. PubMed ID: 29042662
[TBL] [Abstract][Full Text] [Related]
34. Authors' reply to Comment on "No impact of interleukin-28B polymorphisms on spontaneous or drug-induced hepatitis delta virus clearance" [Dig. Liver Dis.2014;46:348-52].
Visco-Comandini U; Lapa D; Taibi C; Angeletti C
Dig Liver Dis; 2014 Aug; 46(8):762. PubMed ID: 24890620
[No Abstract] [Full Text] [Related]
35. Extended treatment duration overcomes the requirement for profound week-4 interferon responsiveness in order for hepatitis C genotype 1 patients with unfavorable IL-28B genotype to achieve sustained virologic response.
Toyoda H; Kumada T
J Clin Virol; 2013 Aug; 57(4):381. PubMed ID: 23688864
[No Abstract] [Full Text] [Related]
36. A perspective on modelling hepatitis C virus infection.
Guedj J; Rong L; Dahari H; Perelson AS
J Viral Hepat; 2010 Dec; 17(12):825-33. PubMed ID: 20723038
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response.
Karaca C; Soyer OM; Baran B; Ormeci AC; Gokturk S; Aydin E; Evirgen S; Akyuz F; Demir K; Besisik F; Kaymakoglu S
Antivir Ther; 2013; 18(4):561-6. PubMed ID: 22976528
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis D Virus and HBsAg Dynamics in the era of new Antiviral Treatments.
Shekhtman L; Duehren S; Etzion O; Cotler SJ; Dahari H
Curr Gastroenterol Rep; 2023 Dec; 25(12):401-412. PubMed ID: 37819559
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.
Klumpp K; Shimada T; Allweiss L; Volz T; Lütgehetmann M; Hartman G; Flores OA; Lam AM; Dandri M
Gastroenterology; 2018 Feb; 154(3):652-662.e8. PubMed ID: 29079518
[TBL] [Abstract][Full Text] [Related]
40. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
Yu ML; Dai CY; Huang JF; Chuang WL
Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
